{
  "name": "Ascelia Pharma",
  "slug": "ascelia-pharma",
  "description": "Statiskt källarkiv med kurshistorik, finansiella rapporter och regulatoriska dokument. För nordiska bolag används Nasdaq Nordic primärt och MFN endast för saknade rapportperioder.",
  "status": "complete",
  "updated_at": "2026-08-07T01:14:22Z",
  "nasdaq_status": "retrieved",
  "latest_market": "2026-08-06: stängning 0.59, volym 670558",
  "mfn_status": "resolved_no_reports",
  "mfn_count": 0,
  "nasdaq_reports_status": "retrieved",
  "reports": {
    "available": true,
    "url": "/company/ascelia-pharma/reports",
    "count": 16,
    "nasdaq_count": 16,
    "mfn_fallback_count": 0,
    "items": [
      {
        "report_key": "2026:q1",
        "period_label": "2026 Q1",
        "date": "2026-05-12",
        "title": "Kvartalsrapport Q1 2026",
        "original_title": "Kvartalsrapport Q1 2026: Orviglance® närmar sig transformerande milstolpar",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b69e833ef3fd325c14b44bfc91e2a9f2f&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
            "title": "Kvartalsrapport Q1 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/afc93eedfdc0d8248fb35c5930da0290d",
            "date": "2026-05-12",
            "period": "2026-q1",
            "form_type": "interim-report",
            "report_key": "2026:q1",
            "filename": "Ascelia_Pharma_Q1_2026_SE.pdf",
            "text_chars": 46956,
            "sha256": "bc77cf42cc12a08c198dfec56f258a6d51ff4f27c64f8bbb0473f328f0c7adbb",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
                "chars": 46956
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:annual",
        "period_label": "2025 Årsredovisning",
        "date": "2026-04-09",
        "title": "Årsredovisning 2025",
        "original_title": "Årsredovisning 2025: Orviglance NDA inskickad till FDA, PDUFA datum satt till Juli 2026",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b09d01f06d38330f139cdb8b92b3580f2&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2025,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2025",
            "title": "Årsredovisning 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a616779d0c144e5181631d424d0a1c6ac",
            "date": "2026-04-09",
            "period": "2025-annual",
            "form_type": "annual-report",
            "report_key": "2025:annual",
            "filename": "Ascelia_Pharma_Arsredovisning_2025.pdf",
            "text_chars": 259489,
            "sha256": "5a1e670cb79ae0cf609fae8beb4c9c0cd92a47ee9f1a4fe17de375ace763b116",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
                "chars": 179252
              },
              {
                "number": 2,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
                "chars": 80235
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q4",
        "period_label": "2025 Q4",
        "date": "2026-02-05",
        "title": "Kvartalsrapport Q4 2025",
        "original_title": "Bokslutskommuniké och Q4 2025: FDA accepterar Orviglance NDA-ansökan för granskning",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b8edbdd8cff5d787e93ebd817fa866254&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2025,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
            "title": "Kvartalsrapport Q4 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ac95cf882f063fb0fdbf3803d3a2928d9",
            "date": "2026-02-05",
            "period": "2025-q4",
            "form_type": "year-end-report",
            "report_key": "2025:q4",
            "filename": "Ascelia_Pharma_Q4_2025.pdf",
            "text_chars": 52909,
            "sha256": "95cbd61adaaf2e96b19e143dc511b14d93d090c3f78a9d27f02ac8269d8d427d",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
                "chars": 52909
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q3",
        "period_label": "2025 Q3",
        "date": "2025-11-05",
        "title": "Kvartalsrapport Q3 2025",
        "original_title": "Delårsrapport Q3 2025: Orviglance NDA-ansökan inskickad till FDA",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b4c0ac7b24fd0b3e05b58b7113c01f556&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
            "title": "Kvartalsrapport Q3 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a0bd38d3d3473553aaf09a09e9a7bc202",
            "date": "2025-11-05",
            "period": "2025-q3",
            "form_type": "interim-report",
            "report_key": "2025:q3",
            "filename": "Ascelia_Pharma_Q3_2025_SE.pdf",
            "text_chars": 51996,
            "sha256": "e1f87ea0d9d73d455a94bd34665de4a24a52e74000297f0b17796b69270b31f7",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
                "chars": 51996
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q2",
        "period_label": "2025 Q2",
        "date": "2025-08-21",
        "title": "Kvartalsrapport Q2 2025",
        "original_title": "Halvårsrapport 2025: Orviglance inlämning av NDA-ansökana närmar sig",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b4e2b23a5f5fff25b28ac4cadfe8da712&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
            "title": "Kvartalsrapport Q2 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a3d4633d3bd8c209d4e385149d182661e",
            "date": "2025-08-21",
            "period": "2025-q2",
            "form_type": "interim-report",
            "report_key": "2025:q2",
            "filename": "Ascelia_Pharma_Q2_2025_SE.pdf",
            "text_chars": 54358,
            "sha256": "51ee868cb16beb7bcaa6aeed20fdcdc0aac937843ddc0becff6f3b78d319e399",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
                "chars": 54358
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q1",
        "period_label": "2025 Q1",
        "date": "2025-05-16",
        "title": "Kvartalsrapport Q1 2025",
        "original_title": "Kvartalsrapport Q1 2025: Positivt utfall från FDA-möte om Orviglance före NDA-ansökan",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b9ea9b36d4b231c94af03a4b9d924ff90&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
            "title": "Kvartalsrapport Q1 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ab0309755cd233bb89a6ff3debac9b3f2",
            "date": "2025-05-16",
            "period": "2025-q1",
            "form_type": "interim-report",
            "report_key": "2025:q1",
            "filename": "Ascelia_Pharma_Q1_2025_SE_250516.pdf",
            "text_chars": 48845,
            "sha256": "788877cceef954e263a215c074756092b5a865bf4d07f9c35a944cf288d9ed08",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
                "chars": 48845
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:annual",
        "period_label": "2024 Årsredovisning",
        "date": "2025-04-11",
        "title": "Årsredovisning 2024",
        "original_title": "Årsredovisning 2024: Orviglance går vidare till registreringsfasen efter framgångsrikt slutförande av fas 3-studie",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b0f00ac372dd574182515b9261b30e206&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2024,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2024",
            "title": "Årsredovisning 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a00c6afb766258f9d091d3cc61d2ade0e",
            "date": "2025-04-11",
            "period": "2024-annual",
            "form_type": "annual-report",
            "report_key": "2024:annual",
            "filename": "Ascelia_Pharma_Arsredovisning_2024.pdf",
            "text_chars": 263104,
            "sha256": "2523d6c1016f772ca129ae42a2ad5fab28b17431c274be29585eabc27293adef",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
                "chars": 176500
              },
              {
                "number": 2,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
                "chars": 86602
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q4",
        "period_label": "2024 Q4",
        "date": "2025-02-07",
        "title": "Kvartalsrapport Q4 2024",
        "original_title": "Q4 och Bokslutskommuniké 2024: Slutförande av fullständig studierapport förstärker framgångsrika resultat av SPARKLE fas-3 studien",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b3632030a6629982bd17878b9cb9d4115&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2024,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
            "title": "Kvartalsrapport Q4 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a3c8b1c0607ebd46fb8d7adda42ef6d0f",
            "date": "2025-02-07",
            "period": "2024-q4",
            "form_type": "year-end-report",
            "report_key": "2024:q4",
            "filename": "Ascelia_Pharma_Q4_2024_SE.pdf",
            "text_chars": 54352,
            "sha256": "fdaa7eaf56e45a1868026ced37edcc3820a1f2e88f14667d1f167bcc54654c69",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
                "chars": 54352
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q3",
        "period_label": "2024 Q3",
        "date": "2024-11-07",
        "title": "Kvartalsrapport Q3 2024",
        "original_title": "Kvartalsrapport Q3: Framgångsrikt utfall av företrädesemission om 105 MSEK förlänger kassalikviditeten till sent 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bc21dfc30d3540aeb444935f06e6972d2&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
            "title": "Kvartalsrapport Q3 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a4a60435dc93d1eb08890a823fc155e1f",
            "date": "2024-11-07",
            "period": "2024-q3",
            "form_type": "interim-report",
            "report_key": "2024:q3",
            "filename": "Ascelia_Pharma_Q3_2024_SE.pdf",
            "text_chars": 54708,
            "sha256": "8051e40d1e7a5358323786a691f7f055eb5418fced2269b42df90f11a851432a",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
                "chars": 54708
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q2",
        "period_label": "2024 Q2",
        "date": "2024-08-15",
        "title": "Kvartalsrapport Q2 2024",
        "original_title": "Halvårsrapport 2024: Orviglance slutför den kliniska utvecklingen med framgångsrik fas 3-studie",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b4956867fb8f131ceadffce5286183d8b&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
            "title": "Kvartalsrapport Q2 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a50f6e76c1a4cfe9dcc6f3f7e6bdbe06f",
            "date": "2024-08-15",
            "period": "2024-q2",
            "form_type": "interim-report",
            "report_key": "2024:q2",
            "filename": "Ascelia_Pharma_Q2_2024_SE_240815.pdf",
            "text_chars": 54245,
            "sha256": "3800d27e1020e4c18138d9c5d2dce7d120b63cdb49e8c8160803a8c825df84dd",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
                "chars": 54245
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q1",
        "period_label": "2024 Q1",
        "date": "2024-05-16",
        "title": "Kvartalsrapport Q1 2024",
        "original_title": "Kvartalsrapport Q1: Primärt effektmått uppnått med starka headline-resultat i fas 3-studien med Orviglance",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bdf1b0389fdef135169b56502e24911a1&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
            "title": "Kvartalsrapport Q1 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a4b3a34203db8ddb9ccdc47c88279ba3f",
            "date": "2024-05-16",
            "period": "2024-q1",
            "form_type": "interim-report",
            "report_key": "2024:q1",
            "filename": "Ascelia_Pharma_Q1_2024_SE_240516.pdf",
            "text_chars": 46622,
            "sha256": "34b7f120f5dd9d0b0db38a27f86da644f9b0e04f8602984926e85f239891ff75",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
                "chars": 46622
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:annual",
        "period_label": "2023 Årsredovisning",
        "date": "2024-04-08",
        "title": "Årsredovisning 2023",
        "original_title": "Årsredovisning 2023: Solida framsteg med slutförd patientrekrytering till Orviglance fas 3 och förväntat headline-resultat i maj 2024",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bda2a301b6d24ae2e9bff4ed8c3672a23&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2023,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2023",
            "title": "Årsredovisning 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a6f550d3eb9eb04ee2ed2f5461835f868",
            "date": "2024-04-08",
            "period": "2023-annual",
            "form_type": "annual-report",
            "report_key": "2023:annual",
            "filename": "Ascelia_Pharma_Arsredovisning_2023.pdf",
            "text_chars": 257086,
            "sha256": "61df62f48fed6af7dad70c02e6d424aa5f716dfc01520f056e23a6fea9714f53",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
                "chars": 176330
              },
              {
                "number": 2,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
                "chars": 80754
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q4",
        "period_label": "2023 Q4",
        "date": "2024-02-09",
        "title": "Kvartalsrapport Q4 2023",
        "original_title": "Q4 och bokslutskommuniké 2023: Stärkt finansiell position inför headline-resultat i maj för den kliniska fas-3 studien SPARKLE",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bc37e6c44f6bae3b8eee4a241226664ea&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2023,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
            "title": "Kvartalsrapport Q4 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a83aa3ac4584a5ed5eb687522f6c53272",
            "date": "2024-02-09",
            "period": "2023-q4",
            "form_type": "year-end-report",
            "report_key": "2023:q4",
            "filename": "Ascelia_Pharma_Q4_2023_SE.pdf",
            "text_chars": 50975,
            "sha256": "7ba68666b6aca63ae4df5542b8ade44ec73c8873506549553a8a48aa897714af",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
                "chars": 50975
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q3",
        "period_label": "2023 Q3",
        "date": "2023-11-08",
        "title": "Kvartalsrapport Q3 2023",
        "original_title": "KVARTALSRAPPORT Q3 2022: Den ny utläsning av bilderna från fas 3-studien SPARKLE fortskrider enligt planen",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=be1dbee39a2436abecbee0763eee739d4&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
            "title": "Kvartalsrapport Q3 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ad8debcc95fb9ebaf2a39f4e11f4cbe83",
            "date": "2023-11-08",
            "period": "2023-q3",
            "form_type": "interim-report",
            "report_key": "2023:q3",
            "filename": "Ascelia_Pharma_Q3_2023_SE_231108.pdf",
            "text_chars": 48935,
            "sha256": "29876da6ecf825218e5bc5c11982d65e0dd23950c7f76e2dc9b8d217165a6c2f",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
                "chars": 48935
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q2",
        "period_label": "2023 Q2",
        "date": "2023-08-18",
        "title": "Kvartalsrapport Q2 2023",
        "original_title": "Halvårsrapport 2023: Ny utläsning krävs efter intraläsarinkonsistens rörande poängsättning av bilder av läsare från fas 3-studien SPARKLE",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b699d093efd0878ee0e9cad791c2bca65&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
            "title": "Kvartalsrapport Q2 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a8e47626daae85e5d3f09d934c5a78640",
            "date": "2023-08-18",
            "period": "2023-q2",
            "form_type": "interim-report",
            "report_key": "2023:q2",
            "filename": "Ascelia_Pharma_Q2_2023_SE_230817_1_0.pdf",
            "text_chars": 50492,
            "sha256": "596d2844d6a7ea6a7ea215ff21620020f1af3d0b026f448b5ec9c8428fed90dd",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
                "chars": 50492
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q1",
        "period_label": "2023 Q1",
        "date": "2023-05-11",
        "title": "Kvartalsrapport Q1 2023",
        "original_title": "KVARTALSRAPPORT Q1 2023: Fas 3 studien för Orviglance, SPARKLE, sista patientens sista besök (Last Patient Last Visit, LPLV) har avslutats",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b4f9bfcf2b2288a03455413497a756177&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
            "title": "Kvartalsrapport Q1 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a38094033dd5f7565b9bd71081841a20d",
            "date": "2023-05-11",
            "period": "2023-q1",
            "form_type": "interim-report",
            "report_key": "2023:q1",
            "filename": "Ascelia_Pharma_Q1_2023_SE_2023_05_11.pdf",
            "text_chars": 40790,
            "sha256": "f9ad05d7bcd9de92ec45b89b29b4bb1304970e81881728c5adc66d210f6a6fba",
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
                "chars": 40790
              }
            ]
          }
        ],
        "alternatives": []
      }
    ]
  },
  "report_count": 16,
  "nasdaq_report_count": 16,
  "mfn_fallback_count": 0,
  "sec_status": "skipped",
  "sec_count": 0,
  "fi_status": "retrieved",
  "fi_summary": {
    "company": "Ascelia Pharma",
    "identity": {
      "issuer": "Ascelia Pharma AB",
      "lei": "5493002YR9VCJJPWYN08",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 98,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "Ascelia Pharma",
      "query": "Ascelia Pharma AB",
      "candidate_count": 345
    },
    "period": {
      "from": "2024-08-07",
      "to": "2026-08-07",
      "years": 2
    },
    "generated_at": "2026-08-07T01:14:22Z",
    "insider": {
      "transactions": 97,
      "all_export_rows": 97,
      "acquisitions": 3,
      "disposals": 8,
      "other": 86,
      "acquisition_value_sek": 136220.0,
      "disposal_value_sek": 529648.61,
      "characters": {
        "Avyttring": 8,
        "Förvärv": 3,
        "Lösen minskning": 38,
        "Lösen ökning": 10,
        "Teckning": 27,
        "Tilldelning": 11
      }
    },
    "short_selling": {
      "aggregate_percent": 0.92,
      "current_public_positions": 0,
      "historical_changes": 16,
      "current_position_sum_over_0_5": 0
    },
    "sources": {
      "insider_register": "https://www.fi.se/sv/vara-register/insynsregistret/",
      "short_register": "https://www.fi.se/sv/vara-register/blankningsregistret/"
    }
  },
  "warnings": [
    "MFN fallback: resolved_no_reports"
  ],
  "source_identity": {
    "nasdaq_reports": {
      "slug": "",
      "instrument_id": "TX2983880",
      "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/ace?id=TX2983880"
    },
    "mfn": {
      "status": "resolved",
      "company_name": "Ascelia Pharma",
      "expected_name": "Ascelia Pharma",
      "match_score": 100.0,
      "slug": "ascelia-pharma",
      "url": "https://mfn.se/all/a/ascelia-pharma",
      "metadata": {
        "country": "Sverige",
        "list": "Small Cap Stockholm",
        "sector": "Hälsovård",
        "industry": "Läkemedel & Handel",
        "website": "https://career.modularfinance.se"
      },
      "ticker_candidates": [],
      "attempts": []
    },
    "sec": null,
    "nasdaq": {
      "instrument_id": "TX2983880",
      "asset_class": "SHARES",
      "isin": "SE0010573113",
      "symbol": "ACE",
      "company": "Ascelia Pharma",
      "market": null,
      "last_sale_price": "SEK 0.59",
      "time_as_of": "2026-08-06"
    },
    "finansinspektionen": {
      "issuer": "Ascelia Pharma AB",
      "lei": "5493002YR9VCJJPWYN08",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 98,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "Ascelia Pharma",
      "query": "Ascelia Pharma AB",
      "candidate_count": 345
    }
  },
  "documents": [
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
      "title": "Kvartalsrapport Q1 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/afc93eedfdc0d8248fb35c5930da0290d",
      "date": "2026-05-12",
      "period": "2026-q1",
      "form_type": "interim-report",
      "report_key": "2026:q1",
      "filename": "Ascelia_Pharma_Q1_2026_SE.pdf",
      "text_chars": 46956,
      "sha256": "bc77cf42cc12a08c198dfec56f258a6d51ff4f27c64f8bbb0473f328f0c7adbb",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
          "chars": 46956
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2025",
      "title": "Årsredovisning 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a616779d0c144e5181631d424d0a1c6ac",
      "date": "2026-04-09",
      "period": "2025-annual",
      "form_type": "annual-report",
      "report_key": "2025:annual",
      "filename": "Ascelia_Pharma_Arsredovisning_2025.pdf",
      "text_chars": 259489,
      "sha256": "5a1e670cb79ae0cf609fae8beb4c9c0cd92a47ee9f1a4fe17de375ace763b116",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
          "chars": 179252
        },
        {
          "number": 2,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
          "chars": 80235
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
      "title": "Kvartalsrapport Q4 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ac95cf882f063fb0fdbf3803d3a2928d9",
      "date": "2026-02-05",
      "period": "2025-q4",
      "form_type": "year-end-report",
      "report_key": "2025:q4",
      "filename": "Ascelia_Pharma_Q4_2025.pdf",
      "text_chars": 52909,
      "sha256": "95cbd61adaaf2e96b19e143dc511b14d93d090c3f78a9d27f02ac8269d8d427d",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
          "chars": 52909
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
      "title": "Kvartalsrapport Q3 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a0bd38d3d3473553aaf09a09e9a7bc202",
      "date": "2025-11-05",
      "period": "2025-q3",
      "form_type": "interim-report",
      "report_key": "2025:q3",
      "filename": "Ascelia_Pharma_Q3_2025_SE.pdf",
      "text_chars": 51996,
      "sha256": "e1f87ea0d9d73d455a94bd34665de4a24a52e74000297f0b17796b69270b31f7",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
          "chars": 51996
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
      "title": "Kvartalsrapport Q2 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a3d4633d3bd8c209d4e385149d182661e",
      "date": "2025-08-21",
      "period": "2025-q2",
      "form_type": "interim-report",
      "report_key": "2025:q2",
      "filename": "Ascelia_Pharma_Q2_2025_SE.pdf",
      "text_chars": 54358,
      "sha256": "51ee868cb16beb7bcaa6aeed20fdcdc0aac937843ddc0becff6f3b78d319e399",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
          "chars": 54358
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
      "title": "Kvartalsrapport Q1 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ab0309755cd233bb89a6ff3debac9b3f2",
      "date": "2025-05-16",
      "period": "2025-q1",
      "form_type": "interim-report",
      "report_key": "2025:q1",
      "filename": "Ascelia_Pharma_Q1_2025_SE_250516.pdf",
      "text_chars": 48845,
      "sha256": "788877cceef954e263a215c074756092b5a865bf4d07f9c35a944cf288d9ed08",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
          "chars": 48845
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2024",
      "title": "Årsredovisning 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a00c6afb766258f9d091d3cc61d2ade0e",
      "date": "2025-04-11",
      "period": "2024-annual",
      "form_type": "annual-report",
      "report_key": "2024:annual",
      "filename": "Ascelia_Pharma_Arsredovisning_2024.pdf",
      "text_chars": 263104,
      "sha256": "2523d6c1016f772ca129ae42a2ad5fab28b17431c274be29585eabc27293adef",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
          "chars": 176500
        },
        {
          "number": 2,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
          "chars": 86602
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
      "title": "Kvartalsrapport Q4 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a3c8b1c0607ebd46fb8d7adda42ef6d0f",
      "date": "2025-02-07",
      "period": "2024-q4",
      "form_type": "year-end-report",
      "report_key": "2024:q4",
      "filename": "Ascelia_Pharma_Q4_2024_SE.pdf",
      "text_chars": 54352,
      "sha256": "fdaa7eaf56e45a1868026ced37edcc3820a1f2e88f14667d1f167bcc54654c69",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
          "chars": 54352
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
      "title": "Kvartalsrapport Q3 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a4a60435dc93d1eb08890a823fc155e1f",
      "date": "2024-11-07",
      "period": "2024-q3",
      "form_type": "interim-report",
      "report_key": "2024:q3",
      "filename": "Ascelia_Pharma_Q3_2024_SE.pdf",
      "text_chars": 54708,
      "sha256": "8051e40d1e7a5358323786a691f7f055eb5418fced2269b42df90f11a851432a",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
          "chars": 54708
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
      "title": "Kvartalsrapport Q2 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a50f6e76c1a4cfe9dcc6f3f7e6bdbe06f",
      "date": "2024-08-15",
      "period": "2024-q2",
      "form_type": "interim-report",
      "report_key": "2024:q2",
      "filename": "Ascelia_Pharma_Q2_2024_SE_240815.pdf",
      "text_chars": 54245,
      "sha256": "3800d27e1020e4c18138d9c5d2dce7d120b63cdb49e8c8160803a8c825df84dd",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
          "chars": 54245
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
      "title": "Kvartalsrapport Q1 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a4b3a34203db8ddb9ccdc47c88279ba3f",
      "date": "2024-05-16",
      "period": "2024-q1",
      "form_type": "interim-report",
      "report_key": "2024:q1",
      "filename": "Ascelia_Pharma_Q1_2024_SE_240516.pdf",
      "text_chars": 46622,
      "sha256": "34b7f120f5dd9d0b0db38a27f86da644f9b0e04f8602984926e85f239891ff75",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
          "chars": 46622
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2023",
      "title": "Årsredovisning 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a6f550d3eb9eb04ee2ed2f5461835f868",
      "date": "2024-04-08",
      "period": "2023-annual",
      "form_type": "annual-report",
      "report_key": "2023:annual",
      "filename": "Ascelia_Pharma_Arsredovisning_2023.pdf",
      "text_chars": 257086,
      "sha256": "61df62f48fed6af7dad70c02e6d424aa5f716dfc01520f056e23a6fea9714f53",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
          "chars": 176330
        },
        {
          "number": 2,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
          "chars": 80754
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
      "title": "Kvartalsrapport Q4 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a83aa3ac4584a5ed5eb687522f6c53272",
      "date": "2024-02-09",
      "period": "2023-q4",
      "form_type": "year-end-report",
      "report_key": "2023:q4",
      "filename": "Ascelia_Pharma_Q4_2023_SE.pdf",
      "text_chars": 50975,
      "sha256": "7ba68666b6aca63ae4df5542b8ade44ec73c8873506549553a8a48aa897714af",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
          "chars": 50975
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
      "title": "Kvartalsrapport Q3 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ad8debcc95fb9ebaf2a39f4e11f4cbe83",
      "date": "2023-11-08",
      "period": "2023-q3",
      "form_type": "interim-report",
      "report_key": "2023:q3",
      "filename": "Ascelia_Pharma_Q3_2023_SE_231108.pdf",
      "text_chars": 48935,
      "sha256": "29876da6ecf825218e5bc5c11982d65e0dd23950c7f76e2dc9b8d217165a6c2f",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
          "chars": 48935
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
      "title": "Kvartalsrapport Q2 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a8e47626daae85e5d3f09d934c5a78640",
      "date": "2023-08-18",
      "period": "2023-q2",
      "form_type": "interim-report",
      "report_key": "2023:q2",
      "filename": "Ascelia_Pharma_Q2_2023_SE_230817_1_0.pdf",
      "text_chars": 50492,
      "sha256": "596d2844d6a7ea6a7ea215ff21620020f1af3d0b026f448b5ec9c8428fed90dd",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
          "chars": 50492
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
      "title": "Kvartalsrapport Q1 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a38094033dd5f7565b9bd71081841a20d",
      "date": "2023-05-11",
      "period": "2023-q1",
      "form_type": "interim-report",
      "report_key": "2023:q1",
      "filename": "Ascelia_Pharma_Q1_2023_SE_2023_05_11.pdf",
      "text_chars": 40790,
      "sha256": "f9ad05d7bcd9de92ec45b89b29b4bb1304970e81881728c5adc66d210f6a6fba",
      "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
          "chars": 40790
        }
      ]
    },
    {
      "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
      "title": "MFN bolagssida och bolagsmetadata",
      "source": "MFN",
      "source_class": "mfn",
      "source_url": "https://mfn.se/all/a/ascelia-pharma",
      "date": null,
      "period": null,
      "form_type": "company-page",
      "report_key": null,
      "filename": "company.txt",
      "text_chars": 11722,
      "sha256": "c494431f8080e7713192e3e3df0fb22ffadd94246fd6e0cb8932d7652178c146",
      "url": "/company/ascelia-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "txt_url": "/company/ascelia-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/ascelia-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
          "chars": 11722
        }
      ]
    }
  ],
  "market_files": [
    {
      "label": "Nasdaq kurshistorik CSV",
      "url": "/company/ascelia-pharma/market/history.csv",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/market/history.csv"
    },
    {
      "label": "Nasdaq kurshistorik JSON",
      "url": "/company/ascelia-pharma/market/history.json",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/market/history.json"
    },
    {
      "label": "Nasdaq manifest JSON",
      "url": "/company/ascelia-pharma/market/manifest.json",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/market/manifest.json"
    },
    {
      "label": "Nasdaq instrumentidentitet JSON",
      "url": "/company/ascelia-pharma/market/instrument.json",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/market/instrument.json"
    },
    {
      "label": "MFN manifest JSON",
      "url": "/company/ascelia-pharma/market/mfn-manifest.json",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/market/mfn-manifest.json"
    },
    {
      "label": "Nasdaq rapportmanifest JSON",
      "url": "/company/ascelia-pharma/market/nasdaq-reports-manifest.json",
      "absolute_url": "https://spela.port0.org/company/ascelia-pharma/market/nasdaq-reports-manifest.json"
    }
  ],
  "sec_facts": {
    "status": "missing",
    "metrics": []
  },
  "morningstar": {
    "configured": false,
    "status": "inte hämtad",
    "captured_at": null,
    "view_count": 0,
    "url": "/company/ascelia-pharma/morningstar"
  },
  "finansinspektionen": {
    "available": true,
    "status": "retrieved",
    "url": "/company/ascelia-pharma/finansinspektionen",
    "transaction_count": 97,
    "aggregate_short_percent": 0.92,
    "files": [
      {
        "filename": "summary.json",
        "label": "Sammanfattning JSON",
        "url": "summary.json"
      },
      {
        "filename": "insider-transactions.csv",
        "label": "Insynstransaktioner CSV",
        "url": "insider-transactions.csv"
      },
      {
        "filename": "insider-transactions.json",
        "label": "Insynstransaktioner JSON",
        "url": "insider-transactions.json"
      },
      {
        "filename": "short-current.json",
        "label": "Aktuella blankningspositioner JSON",
        "url": "short-current.json"
      },
      {
        "filename": "short-history.json",
        "label": "Historiska blankningspositioner JSON",
        "url": "short-history.json"
      },
      {
        "filename": "short-aggregate.json",
        "label": "Aggregerad blankning JSON",
        "url": "short-aggregate.json"
      },
      {
        "filename": "manifest.json",
        "label": "Hämtningsmanifest JSON",
        "url": "manifest.json"
      }
    ]
  },
  "llms_url": "/company/ascelia-pharma/llms.txt",
  "json_url": "/company/ascelia-pharma/company.json",
  "document_index_url": "/company/ascelia-pharma/documents.json",
  "absolute_url": "https://spela.port0.org/company/ascelia-pharma"
}